Fust Matthew K
Director at CRNX; Director at NMRA; Director at RARE, and 4 more
- Sold, on record
- $15.2M
- Dollars the filings state
- Form 4 sales
- 39
- Latest Sep 26, 2025
- Form 144 notices
- 4
- Proposed sales
- Companies
- 7
- Filed as an executive or holder
Companies
- CRNXCrinetics Pharmaceuticals, Inc.Director
- NMRANeumora Therapeutics, Inc.Director
- RAREUltragenyx Pharmaceutical Inc.Director
- ATRAAtara Biotherapeutics, Inc.Director
- Dermira, Inc.Director
- MGNXMACROGENICS INCDirector
- ONYX PHARMACEUTICALS INCEVP & Chief Financial Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- CRNX115,200 shares
- ONYX PHARMACEUTICALS INC85,757 shares
- RARE33,445 shares
- ATRA25,640 shares
- NMRA21,788 shares
- Dermira, Inc.16,000 shares
- MGNX6,924 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 144 notice RARENoticeMar 7, 2024 2024
Filed to sell 12,195 shares ($620k)
Fust Matthew K, Director
10b5-1 planFirst sale on recordFiling
- 2 Form 4 sale RARERoutineMar 7, 2024 same day
Sold 12,195 shares at $50.88 ($620k)
Fust Matthew K, Director
10b5-1 planSold 45.1% of holdings ($1.4M position)14,860 shares leftFirst sale on recordFollows a Form 144Filing
- 3 Form 144 notice CRNXNoticeMar 20, 2024 +13 days
Filed to sell 60,000 shares ($2.6M)
Fust Matthew K, Director
10b5-1 planFiling
- 4 Form 4 sale CRNXRoutineMar 20, 2024 same day
Sold 60,000 shares at $44.14 ($2.6M)
Fust Matthew K, Director
10b5-1 planSold 76.4% of holdings ($3.5M position)18,536 shares leftFollows a Form 144Filing
- 5 Form 144 notice NMRANoticeOct 17, 2024 +211 days
Filed to sell 7,739 shares ($132k)
Fust Matthew K, Director
10b5-1 planFirst sale on recordFiling
- 6 Form 144 notice NMRANoticeOct 18, 2024 +1 day
Filed to sell 14,049 shares ($239k)
Fust Matthew K, Director
10b5-1 planFirst sale on recordFiling
- 7 Form 4 sale NMRARoutineOct 18, 2024 same day
Sold 21,788 shares at $17.02 ($371k)
Fust Matthew K, Director
10b5-1 planSold 52% of holdings ($713k position)20,100 shares leftFirst sale on recordFollows a Form 144Filing
- 8 Form 4 sale CRNXRoutineSep 26, 2025 +343 days
Sold 16,000 shares at $44.75 ($716k)
Fust Matthew K, Director
10b5-1 planSold 41.2% of holdings ($1.7M position)22,836 shares leftFiling
Every transaction
Loading transactions…
Sales and notices (43)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sep 26, 2025 | Sep 30, 2025 | CRNX | Director | Form 4 sale | 16,000 | $716k | 41.2% | Routine | SEC |
| Oct 18, 2024 | Oct 18, 2024 | NMRA | Director | Form 4 sale | 21,788 | $371k | 52.0% | Routine | SEC |
| Oct 18, 2024 | Oct 18, 2024 | NMRA | Director | Form 144 notice | 14,049 | $239k | Notice | SEC | |
| Oct 17, 2024 | Oct 17, 2024 | NMRA | Director | Form 144 notice | 7,739 | $132k | Notice | SEC | |
| Mar 20, 2024 | Mar 22, 2024 | CRNX | Director | Form 4 sale | 60,000 | $2.6M | 76.4% | Routine | SEC |
| Mar 20, 2024 | Mar 20, 2024 | CRNX | Director | Form 144 notice | 60,000 | $2.6M | Notice | SEC | |
| Mar 7, 2024 | Mar 11, 2024 | RARE | Director | Form 4 sale | 12,195 | $620k | 45.1% | Routine | SEC |
| Mar 7, 2024 | Mar 7, 2024 | RARE | Director | Form 144 notice | 12,195 | $620k | Notice | SEC | |
| Jul 13, 2022 | Jul 15, 2022 | CRNX | Director | Form 4 sale | 5,700 | $119k | 31.3% | Unusual | SEC |
| Nov 4, 2021 | Nov 5, 2021 | ATRA | Director | Form 4 sale | 13,354 | $260k | 29.8% | Unusual | SEC |
| Nov 1, 2021 | Nov 3, 2021 | CRNX | Director | Form 4 sale | 8,954 | $228k | 41.7% | Unusual | SEC |
| Sep 8, 2021 | Sep 9, 2021 | CRNX | Director | Form 4 sale | 6,046 | $154k | 32.5% | Unusual | SEC |
| Jul 26, 2021 | Jul 27, 2021 | CRNX | Director | Form 4 sale | 5,000 | $98k | 28.5% | Unusual | SEC |
| Jul 19, 2021 | Jul 20, 2021 | CRNX | Director | Form 4 sale | 5,000 | $98k | 28.5% | Unusual | SEC |
| Jul 12, 2021 | Jul 13, 2021 | CRNX | Director | Form 4 sale | 5,000 | $104k | 28.5% | Unusual | SEC |
| Jul 6, 2020 | Jul 8, 2020 | RARE | Director | Form 4 sale | 6,181 | $556k | 31.3% | Unusual | SEC |
| Jul 1, 2020 | Jul 6, 2020 | RARE | Director | Form 4 sale | 5,000 | $425k | 27.0% | Unusual | SEC |
| May 18, 2020 | May 19, 2020 | RARE | Director | Form 4 sale | 1,875 | $141k | 14.6% | Plan not stated | SEC |
| Apr 22, 2020 | Apr 24, 2020 | RARE | Director | Form 4 sale | 1,875 | $122k | 12.7% | Plan not stated | SEC |
| Dec 24, 2019 | Dec 26, 2019 | Dermira, Inc. | Director | Form 4 sale | 3,000 | $45k | 37.3% | Unusual | SEC |
| Dec 16, 2019 | Dec 18, 2019 | CRNX | Director | Form 4 sale | 3,500 | $79k | 21.8% | Plan not stated | SEC |
| Dec 12, 2019 | Dec 13, 2019 | Dermira, Inc. | Director | Form 4 sale | 3,000 | $36k | 27.1% | Unusual | SEC |
| Sep 12, 2019 | Sep 16, 2019 | Dermira, Inc. | Director | Form 4 sale | 6,000 | $53k | 35.2% | Unusual | SEC |
| Feb 6, 2019 | Feb 8, 2019 | MGNX | Director | Form 4 sale | 6,924 | $203k | 93.3% | Unusual | SEC |
| Oct 19, 2018 | Oct 19, 2018 | Dermira, Inc. | Director | Form 4 sale | 4,000 | $55k | 22.2% | Plan not stated | SEC |
| May 30, 2018 | May 30, 2018 | RARE | Director | Form 4 sale | 6,319 | $455k | 41.9% | Unusual | SEC |
| May 14, 2018 | May 16, 2018 | ATRA | Director | Form 4 sale | 12,286 | $535k | 38.3% | Unusual | SEC |
| Aug 8, 2013 | Aug 12, 2013 | ONYX PHARMACEUTICALS INC | EVP & Chief Financial Officer | Form 4 sale | 2,492 | $319k | 5.8% | Plan not stated | SEC |
| Jul 26, 2013 | Jul 29, 2013 | ONYX PHARMACEUTICALS INC | EVP & Chief Financial Officer | Form 4 sale | 6,043 | $789k | 12.4% | Plan not stated | SEC |
| Jul 2, 2013 | Jul 5, 2013 | ONYX PHARMACEUTICALS INC | EVP & Chief Financial Officer | Form 4 sale | 1,551 | $206k | 3.1% | Plan not stated | SEC |
| May 13, 2013 | May 15, 2013 | ONYX PHARMACEUTICALS INC | EVP & Chief Financial Officer | Form 4 sale | 10,269 | $1M | 17.0% | Plan not stated | SEC |
| Apr 15, 2013 | Apr 16, 2013 | ONYX PHARMACEUTICALS INC | EVP & Chief Financial Officer | Form 4 sale | 1,347 | $128k | 2.6% | Plan not stated | SEC |
| Apr 1, 2013 | Apr 3, 2013 | ONYX PHARMACEUTICALS INC | EVP & Chief Financial Officer | Form 4 sale | 3,861 | $333k | 7.0% | Plan not stated | SEC |
| Feb 28, 2013 | Mar 4, 2013 | ONYX PHARMACEUTICALS INC | EVP & Chief Financial Officer | Form 4 sale | 15,000 | $1.2M | 24.9% | Unusual | SEC |
| Jan 10, 2013 | Jan 11, 2013 | ONYX PHARMACEUTICALS INC | EVP & Chief Financial Officer | Form 4 sale | 10,199 | $866k | 16.9% | Unusual | SEC |
| Aug 6, 2012 | Aug 8, 2012 | ONYX PHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 22,009 | $1.6M | 25.8% | Unusual | SEC |
| Jul 25, 2012 | Jul 27, 2012 | ONYX PHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 5,207 | $385k | 7.1% | Unusual | SEC |
| Mar 2, 2012 | Mar 6, 2012 | ONYX PHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 592 | $22k | 1.2% | Plan not stated | SEC |
| Jan 6, 2012 | Jan 10, 2012 | ONYX PHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 1,789 | $78k | 3.9% | Plan not stated | SEC |
| Nov 18, 2011 | Nov 21, 2011 | ONYX PHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 867 | $33k | 1.9% | Plan not stated | SEC |
| Apr 1, 2011 | Apr 4, 2011 | ONYX PHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 800 | $28k | 1.7% | Plan not stated | SEC |
| Jan 6, 2011 | Jan 7, 2011 | ONYX PHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 1,812 | $68k | 9.1% | Plan not stated | SEC |
| Jan 6, 2010 | Jan 7, 2010 | ONYX PHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 1,919 | $57k | 14.2% | Plan not stated | SEC |